Patient Subgroup Outcomes with GPRC5D Bispecifics
Panelists discuss how certain patient subgroups, such as those with high-risk cytogenetics or extramedullary disease, may experience different outcomes with GPRC5D bispecific therapies, though more data is needed to draw definitive conclusions about subgroup-specific responses.
EP: 1.GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma
EP: 2.Real-World Efficacy of GPRC5D Bispecifics vs Clinical Trials
EP: 3.Patient Selection Factors for GPRC5D-Targeted Therapies
EP: 4.Patient Subgroup Outcomes with GPRC5D Bispecifics
EP: 5.Biomarkers and Clinical Features Influencing GPRC5D Bispecific Initiation
EP: 6.Integration of GPRC5D-Targeted Therapies in RRMM Treatment
EP: 7.Prevalent Safety Concerns in Community Settings
EP: 8.Challenging Adverse Events with GPRC5D-Targeted Therapies
EP: 9.Long-Term Monitoring Protocols for Bispecific Therapy Complications
EP: 10.Proactive Steps for Mitigating GPRC5D Therapy Adverse Events
EP: 11.Logistical Barriers in Implementing GPRC5D-Targeted Therapies
EP: 12.Healthcare Resource Utilization Impact of GPRC5D-Targeted Therapies
EP: 13.Resources Needed for Enhanced Bispecific Implementation
EP: 14.Areas for Improvement in Real-World GPRC5D-Targeted Therapy Application
EP: 15.Future Impact of GPRC5D-Targeted Therapies on RRMM Treatment
EP: 16.Unmet Needs and Future Directions for GPRC5D Bispecific Therapy
- Have any patient subgroups demonstrated notably different outcomes with these GPRC5D bispecific therapies?
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
